Orthotopic Bone Formation by Streamlined Engineering and Devitalization of Human Hypertrophic Cartilage.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Sep 2020
Historique:
received: 02 09 2020
revised: 22 09 2020
accepted: 26 09 2020
entrez: 3 10 2020
pubmed: 4 10 2020
medline: 24 2 2021
Statut: epublish

Résumé

Most bones of the human body form and heal through endochondral ossification, whereby hypertrophic cartilage (HyC) is formed and subsequently remodeled into bone. We previously demonstrated that HyC can be engineered from human mesenchymal stromal cells (hMSC), and subsequently devitalized by apoptosis induction. The resulting extracellular matrix (ECM) tissue retained osteoinductive properties, leading to ectopic bone formation. In this study, we aimed at engineering and devitalizing upscaled quantities of HyC ECM within a perfusion bioreactor, followed by in vivo assessment in an orthotopic bone repair model. We hypothesized that the devitalized HyC ECM would outperform a clinical product currently used for bone reconstructive surgery. Human MSC were genetically engineered with a gene cassette enabling apoptosis induction upon addition of an adjuvant. Engineered hMSC were seeded, differentiated, and devitalized within a perfusion bioreactor. The resulting HyC ECM was subsequently implanted in a 10-mm rabbit calvarial defect model, with processed human bone (Maxgraft

Identifiants

pubmed: 33008121
pii: ijms21197233
doi: 10.3390/ijms21197233
pmc: PMC7582540
pii:
doi:

Substances chimiques

Bone Substitutes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Eurostars Program
ID : E!7865
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 310030-133110

Références

Transfus Med Hemother. 2012 Feb;39(1):36-40
pubmed: 22896765
Bone. 2016 Oct;91:30-8
pubmed: 27353702
Bone. 2015 Jan;70:66-72
pubmed: 25260931
Sci Transl Med. 2014 Apr 16;6(232):232fs16
pubmed: 24739757
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3997-4002
pubmed: 23401508
Bone Joint J. 2016 Jan;98-B(1 Suppl A):6-9
pubmed: 26733632
Adv Drug Deliv Rev. 2015 Apr;84:1-29
pubmed: 25236302
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17426-31
pubmed: 25422415
Blood. 2013 Nov 14;122(20):3461-72
pubmed: 24016461
Nat Rev Endocrinol. 2016 Apr;12(4):203-21
pubmed: 26893264
Sports Med Arthrosc Rev. 2007 Sep;15(3):106-13
pubmed: 17700369
Biomaterials. 2019 Oct;218:119336
pubmed: 31310952
BMC Musculoskelet Disord. 2011 Jan 31;12:31
pubmed: 21281488
Semin Cell Dev Biol. 2008 Oct;19(5):459-66
pubmed: 18692584
Biomaterials. 2011 Apr;32(12):3233-43
pubmed: 21296410
Methods Mol Biol. 2016;1416:413-24
pubmed: 27236686
Adv Biochem Eng Biotechnol. 2013;129:73-88
pubmed: 22457052
Tissue Eng. 2007 Aug;13(8):2021-8
pubmed: 17590148
Stem Cells. 2014 Jun;32(6):1408-19
pubmed: 24578244
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7251-6
pubmed: 20406908
Cell Tissue Bank. 2014 Sep;15(3):307-17
pubmed: 23999650
Tissue Eng Part A. 2009 Mar;15(3):635-43
pubmed: 18759673
J Biomech. 2008 Oct 20;41(14):2918-25
pubmed: 18789444
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Adv Drug Deliv Rev. 2018 Apr;129:285-294
pubmed: 29357301
Stem Cells. 2005 Sep;23(8):1066-72
pubmed: 16002780
J Tissue Eng Regen Med. 2016 Apr;10(4):E250-62
pubmed: 23922276
Tissue Eng Part B Rev. 2014 Dec;20(6):596-608
pubmed: 24749845
J Cell Biochem. 2014 Jun;115(6):1089-96
pubmed: 24357502
J Tissue Eng Regen Med. 2015 Aug;9(8):889-902
pubmed: 24916192
Biomaterials. 2013 Aug;34(26):6099-108
pubmed: 23721795
Nat Rev Rheumatol. 2015 Jan;11(1):45-54
pubmed: 25266456
Glycobiology. 2003 Sep;13(9):647-53
pubmed: 12773478
Stem Cell Res Ther. 2015 Apr 23;6:84
pubmed: 25900045
Tissue Eng Part A. 2009 Mar;15(3):625-34
pubmed: 18759672
Bone. 2011 Feb;48(2):171-81
pubmed: 20932947
Nat Methods. 2013 Aug;10(8):788-94
pubmed: 23793238
Trends Mol Med. 2011 Aug;17(8):424-32
pubmed: 21514224
Biotechnol J. 2013 Jun;8(6):644-54
pubmed: 23625834

Auteurs

Sébastien Pigeot (S)

Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Paul Emile Bourgine (PE)

Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Jaquiery Claude (J)

Department of Surgery, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Celeste Scotti (C)

Novartis Institutes for Biomedical Research, 4056 Basel, Switzerland.
IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.

Adam Papadimitropoulos (A)

Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Atanas Todorov (A)

Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Christian Epple (C)

Department of Surgery, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Giuseppe M Peretti (GM)

IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy.
Department of Biomedical Sciences for Health, University of Milan, 20133 Milan, Italy.

Ivan Martin (I)

Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
Department of Surgery, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH